PRKAA2 and diabetic cardiomyopathy: Using an ex-vivo model of diabetic cardiomyopathy induced by advanced glycation end-products (AGE) in engineered cardiac tissue and type 2 diabetic mice model, it has been demonstrated that AMPKα2 is crucial for the sulforaphane-associated prevention of cardiomyopathy by inhibiting ferroptosis.